Reducing transmission of SARS-CoV-2 with intranasal prophylaxis.
作者信息
Boiardi Federico, Stebbing Justin
机构信息
Colegio Internacional SEK-El Castillo, Madrid, Spain.
Department of Surgery and Cancer, Imperial College, London, UK.
出版信息
EBioMedicine. 2021 Jan;63:103170. doi: 10.1016/j.ebiom.2020.103170. Epub 2020 Dec 16.
Abstract
摘要
相似文献
1
Reducing transmission of SARS-CoV-2 with intranasal prophylaxis.通过鼻内预防减少严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的传播。
EBioMedicine. 2021 Jan;63:103170. doi: 10.1016/j.ebiom.2020.103170. Epub 2020 Dec 16.
2
Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets.鼻内融合抑制性脂肽可预防雪貂中严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的直接接触传播。
Science. 2021 Mar 26;371(6536):1379-1382. doi: 10.1126/science.abf4896. Epub 2021 Feb 17.
3
Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.预防性鼻腔内给予 TLR2/6 激动剂可减少 SARS-CoV-2 挑战雪貂模型的上呼吸道病毒脱落。
EBioMedicine. 2021 Jan;63:103153. doi: 10.1016/j.ebiom.2020.103153. Epub 2020 Dec 3.
4
Therapeutic Measures for the Novel Coronavirus: A Review of Current Status and Future Perspective.新型冠状病毒的治疗措施：现状与未来展望综述。
Curr Mol Med. 2021;21(7):562-572. doi: 10.2174/1566524020666201203170230.
5
Passive immunization and its rebirth in the era of the COVID-19 pandemic.被动免疫及其在 COVID-19 大流行时代的复兴。
Int J Antimicrob Agents. 2021 Mar;57(3):106275. doi: 10.1016/j.ijantimicag.2020.106275. Epub 2021 Jan 2.
6
Precision therapeutic targets for COVID-19.针对 COVID-19 的精准治疗靶点。
Virol J. 2021 Mar 29;18(1):66. doi: 10.1186/s12985-021-01526-y.
7
Emerging treatment strategies for COVID-19 infection.针对 COVID-19 感染的新兴治疗策略。
Clin Exp Med. 2021 May;21(2):167-179. doi: 10.1007/s10238-020-00671-y. Epub 2020 Oct 30.
8
Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19.新冠病毒治疗和诊断方法的最新进展。
AAPS J. 2021 Jan 5;23(1):14. doi: 10.1208/s12248-020-00532-2.
9
COVID-19: Transmission, prevention, and potential therapeutic opportunities.新型冠状病毒肺炎：传播、预防和潜在治疗机会。
Clin Chim Acta. 2020 Sep;508:254-266. doi: 10.1016/j.cca.2020.05.044. Epub 2020 May 29.
10
SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments.SARS-CoV-2：感染引起的免疫反应和疫苗及治疗的发展。
Front Immunol. 2020 Dec 11;11:569760. doi: 10.3389/fimmu.2020.569760. eCollection 2020.
引用本文的文献
1
Clinical outcomes of Omicron infection and vaccine acceptance among pediatric liver transplant recipients: insights from a cross-sectional survey.奥密克戎感染和疫苗接种在儿科肝移植受者中的临床结局：来自横断面调查的见解。
Virol J. 2024 Nov 22;21(1):299. doi: 10.1186/s12985-024-02531-7.
2
AYURAKSHA, a prophylactic Ayurvedic immunity boosting kit reducing positivity percentage of IgG COVID-19 among frontline Indian Delhi police personnel: A non-randomized controlled intervention trial.AYURAKSHA，一种预防性阿育吠陀免疫增强工具包，可降低印度德里一线警务人员 IgG COVID-19 的阳性率：一项非随机对照干预试验。
Front Public Health. 2022 Aug 16;10:920126. doi: 10.3389/fpubh.2022.920126. eCollection 2022.
3
Effect of Prophylactic Use of Intranasal Oil Formulations in the Hamster Model of COVID-19.鼻内油剂配方预防性使用在新冠病毒仓鼠模型中的作用
Front Pharmacol. 2021 Oct 14;12:746729. doi: 10.3389/fphar.2021.746729. eCollection 2021.
本文引用的文献
1
Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets.鼻内融合抑制性脂肽可预防雪貂中严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的直接接触传播。
Science. 2021 Mar 26;371(6536):1379-1382. doi: 10.1126/science.abf4896. Epub 2021 Feb 17.
2
The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins.SARS-CoV-2 刺突蛋白对哺乳动物 ACE2 蛋白具有广泛的嗜性。
PLoS Biol. 2020 Dec 21;18(12):e3001016. doi: 10.1371/journal.pbio.3001016. eCollection 2020 Dec.
3
Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.预防性鼻腔内给予 TLR2/6 激动剂可减少 SARS-CoV-2 挑战雪貂模型的上呼吸道病毒脱落。
EBioMedicine. 2021 Jan;63:103153. doi: 10.1016/j.ebiom.2020.103153. Epub 2020 Dec 3.
4
What Is the Best Drug to Treat COVID-19? The Need for Randomized Controlled Trials.治疗 COVID-19 的最佳药物是什么？需要进行随机对照试验。
Med. 2020 Dec 18;1(1):9-10. doi: 10.1016/j.medj.2020.04.002. Epub 2020 May 19.
5
Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice.TLR2 激动剂 Pam2Cys 经鼻腔给药可迅速为小鼠提供抗流感保护。
Mol Pharm. 2012 Sep 4;9(9):2710-8. doi: 10.1021/mp300257x. Epub 2012 Aug 3.
6
The synthetic bacterial lipopeptide Pam3CSK4 modulates respiratory syncytial virus infection independent of TLR activation.合成细菌脂肽 Pam3CSK4 可调节呼吸道合胞病毒感染，而不依赖 TLR 激活。
PLoS Pathog. 2010 Aug 19;6(8):e1001049. doi: 10.1371/journal.ppat.1001049.
7
Identification of ferret ACE2 and its receptor function for SARS-coronavirus.雪貂血管紧张素转换酶2的鉴定及其对严重急性呼吸综合征冠状病毒的受体功能。
Adv Exp Med Biol. 2006;581:519-22. doi: 10.1007/978-0-387-33012-9_93.
Zotero 插件